Atsena Therapeutics announced in a press release that the FDA granted its gene therapy product candidate, ATSN-201, the regenerative medicine advanced therapy (RMAT) designation to treat X-linked ...

Beth Marsh is stepping into the role of Neurotech Pharmaceuticals’ chief commercial officer (CCO) beginning April 28. Marsh will lead the organization, particularly as it prepares for the US launch of ...

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications. The US Food and Drug ...

As part of its five-year strategic plan, Prevent Blindness has promoted five individuals to further the organization’s mission. Prevent Blindness has promoted five leaders to further its efforts and ...

A new Chinese report recognized that social media smartphone application–based interventions significantly improved follow-up adherence and increased parental knowledge among families of children with ...

Companies working in the retina space have announced that data from clinical trials will be shared at this year’s meeting in Fort Lauderdale, Florida. Retina World Congress 2025 will take place May ...

Aviceda Therapeutics recently appointed Jeffrey Nau, PhD, MMS, as chief executive officer. Nau comes to Aviceda with more than 20 years of experience leading and expanding biotechnology and ...

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME). Vantage ...

Eyestem Research announced positive results from its phase 1 trial (NCT06394232) evaluating its investigational drug product, Eyecyte-RPE, in patients with geographic atrophy (GA) secondary to dry age ...

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for broadening the dosing schedule to include every 4-week dosing across approved ...

Regeneron has proposed a longer dosing duration for the high-dose (HD) formulation of aflibercept (EYLEA HD). The FDA is expected to release is decision on this dosing duration by April 20, 2025. 1 ...